PMID: 2123477Dec 15, 1990Paper

Lymphokine-activated killer cell cytotoxicity against human colon carcinomas enhanced by monoclonal antibody D612

International Journal of Cancer. Journal International Du Cancer
T K PendurthiF J Primus

Abstract

The antibody-dependent cellular cytotoxicity (ADCC) properties of a murine monoclonal antibody (MAb), designated D612 (IgG2a), which reacts with human colon carcinomas, was studied using normal human peripheral blood lymphocytes (PBMNC). Although the level of ADCC of PBMNC with D612 varied among different donors, it was 20 to 30 times higher than the lytic activity of control cultures containing isotype-matched control MAb. Incubation of PBMNC with recombinant interleukin-2 (IL-2) resulted in a 2- to 5-fold augmentation in the cytotoxicity of effector cells exposed to MAb. This augmentation was apparent after subtracting nonspecific cellular cytotoxicity from the total cytotoxicity mediated by activated effector cells in the presence of D612. Optimal stimulation of specific ADCC with IL-2 appeared after 24 hr of culture in 500 U/ml of IL-2, resulting in a 3.8 +/- 1.7 fold increase in lytic units. However, stimulation of ADCC was also evident at 10 U/ml of IL-2. Furthermore, antibody dose titrations with untreated and IL-2 activated effectors showed that the threshold dose of MAb needed for efficient ADCC was reduced by 200-fold with IL-2. Depletion of FcR gamma III-positive lymphoid cells markedly reduced D612 ADCC, demonstrati...Continue Reading

References

Mar 1, 1979·Proceedings of the National Academy of Sciences of the United States of America·M HerlynH Koprowski
Mar 1, 1989·Immunology Today·M W FangerP M Guyre
Apr 15, 1989·International Journal of Cancer. Journal International Du Cancer·R MuraroJ Schlom
Jun 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·A F LoBuglioM B Khazaeli
Sep 1, 1988·Cellular Immunology·A EisenthalS A Rosenberg
Sep 7, 1988·Journal of the National Cancer Institute·J R Ortaldo, D L Longo
Oct 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·C J HonsikR A Reisfeld
Jul 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·Z SteplewskiH Koprowski
Aug 17, 1988·Journal of the National Cancer Institute·A F LoBuglioR H Wheeler
Sep 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·I HellströmK E Hellström
Sep 1, 1987·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N K CheungN A Berger
Feb 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·A N HoughtonL J Old
Mar 1, 1985·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G E GoodmanK E Hellström
Apr 1, 1980·The Biochemical Journal·D W Mason, A F Williams
Mar 1, 1981·Cellular Immunology·D G FischerH S Koren

❮ Previous
Next ❯

Citations

Jul 26, 2002·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Haruhiko NakamuraHarubumi Kato
May 31, 1994·Annals of the New York Academy of Sciences·F J PrimusS V Kashmiri
Apr 18, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jesús G BerdejaIan W Flinn

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.

Adrenocortical Carcinoma

Adrenocortical carcinoma (ACC) is a rare malignancy of the adrenal cortex, associated with a generally dismal prognosis owing to its aggressive behavior. Here are the latest discoveries pertaining to this disease.